HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Carsten Denkert Selected Research

taxane

10/2021Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
7/2020PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
1/2018Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
11/2017Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
10/2017Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
10/2017Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
4/2017pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.
10/2016Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
3/2016Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
7/2015Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Carsten Denkert Research Topics

Disease

167Neoplasms (Cancer)
11/2022 - 03/2002
141Breast Neoplasms (Breast Cancer)
04/2022 - 06/2003
51Carcinoma (Carcinomatosis)
01/2022 - 03/2002
34Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 10/2002
31Triple Negative Breast Neoplasms
10/2022 - 01/2013
12Pathologic Complete Response
11/2021 - 05/2012
12Neoplasm Metastasis (Metastasis)
10/2019 - 11/2007
11Adenocarcinoma
01/2022 - 01/2003
8Colorectal Neoplasms (Colorectal Cancer)
01/2019 - 01/2003
7Carcinogenesis
01/2021 - 06/2005
6Ovarian Epithelial Carcinoma
01/2022 - 11/2007
4Colonic Neoplasms (Colon Cancer)
01/2018 - 09/2005
4Pancreatic Neoplasms (Pancreatic Cancer)
08/2016 - 01/2005
3Renal Cell Carcinoma (Grawitz Tumor)
10/2022 - 09/2005
3Inflammation (Inflammations)
10/2022 - 02/2004
3Disease Progression
01/2020 - 04/2005
3Noninfiltrating Intraductal Carcinoma (DCIS)
10/2019 - 04/2012
3Melanoma (Melanoma, Malignant)
11/2017 - 01/2002
3Stomach Neoplasms (Stomach Cancer)
05/2012 - 04/2006
3Residual Neoplasm
12/2009 - 06/2009
3Prostatic Neoplasms (Prostate Cancer)
02/2008 - 08/2004
3Adenoma (Adenomas)
02/2005 - 06/2002
2Rhabdomyosarcoma
11/2022 - 11/2021
2Hemorrhage
10/2020 - 01/2012

Drug/Important Bio-Agent (IBA)

48Proteins (Proteins, Gene)FDA Link
10/2022 - 03/2002
44Biomarkers (Surrogate Marker)IBA
10/2022 - 06/2005
35Estrogen ReceptorsIBA
01/2022 - 06/2003
33Messenger RNA (mRNA)IBA
10/2022 - 03/2002
28Hormones (Hormone)IBA
01/2022 - 01/2009
22ParaffinIBA
07/2020 - 06/2002
21taxaneIBA
10/2021 - 01/2007
18Formaldehyde (Formol)FDA Link
07/2020 - 09/2003
16Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2022 - 04/2006
16human ERBB2 proteinIBA
01/2021 - 01/2009
15Paclitaxel (Taxol)FDA LinkGeneric
10/2022 - 04/2006
15AnthracyclinesIBA
07/2020 - 01/2009
13Immune Checkpoint InhibitorsIBA
10/2022 - 03/2016
13Biological ProductsIBA
01/2022 - 11/2007
12Carboplatin (JM8)FDA LinkGeneric
10/2022 - 06/2014
12Epirubicin (Ellence)FDA LinkGeneric
10/2022 - 01/2012
11Phenobarbital (Luminal)FDA Link
01/2022 - 11/2010
11RNA (Ribonucleic Acid)IBA
11/2021 - 10/2002
11Trastuzumab (Herceptin)FDA Link
01/2020 - 07/2011
11Cyclooxygenase 2 (Cyclooxygenase-2)IBA
01/2009 - 03/2002
10Protein Isoforms (Isoforms)IBA
04/2022 - 06/2003
10PlatinumIBA
11/2021 - 01/2007
9DNA (Deoxyribonucleic Acid)IBA
01/2021 - 11/2009
8Pharmaceutical PreparationsIBA
11/2022 - 11/2003
8130-nm albumin-bound paclitaxelIBA
01/2022 - 10/2015
8Progesterone Receptors (Progesterone Receptor)IBA
09/2021 - 01/2009
8LipidsIBA
05/2021 - 09/2008
7Doxorubicin (Adriamycin)FDA LinkGeneric
10/2022 - 04/2006
7ErbB Receptors (EGF Receptor)IBA
10/2021 - 01/2010
6Poly(ADP-ribose) Polymerase InhibitorsIBA
04/2022 - 06/2011
5GemcitabineFDA Link
01/2021 - 08/2016
5Carrier Proteins (Binding Protein)IBA
10/2020 - 05/2009
5Bevacizumab (Avastin)FDA Link
01/2020 - 01/2012
5Histone Deacetylases (Histone Deacetylase)IBA
04/2013 - 02/2008
5Histone Deacetylase InhibitorsIBA
11/2009 - 02/2008
5Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
03/2007 - 06/2003
4Cisplatin (Platino)FDA LinkGeneric
11/2022 - 04/2006
4B7-H1 AntigenIBA
12/2021 - 01/2016
4LigandsIBA
01/2019 - 09/2014
4MicroRNAs (MicroRNA)IBA
10/2018 - 02/2010
4Phosphotransferases (Kinase)IBA
01/2018 - 01/2002
4Glutamine (L-Glutamine)FDA Link
01/2016 - 11/2012
4ELAV-Like Protein 1IBA
02/2008 - 01/2004
4Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
04/2006 - 03/2002
4Polo-Like Kinase 1IBA
04/2006 - 08/2004
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2022 - 01/2012
3liposomal doxorubicin (Doxil)FDA Link
01/2022 - 01/2019
3Matrix Metalloproteinases (MMPs)IBA
01/2022 - 05/2003
3CytokinesIBA
01/2022 - 01/2002
3Estrogens (Estrogen)FDA Link
01/2021 - 12/2009
3Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
07/2020 - 10/2014
3Epidermal Growth Factor (EGF)IBA
07/2020 - 02/2017
3Poly Adenosine Diphosphate RiboseIBA
02/2020 - 06/2011
3Androgen Receptors (Androgen Receptor)IBA
02/2020 - 11/2011
3EnzymesIBA
02/2020 - 03/2002
3ElementsIBA
11/2017 - 11/2015
3Indicators and Reagents (Reagents)IBA
04/2017 - 02/2008
3InterferonsIBA
01/2017 - 01/2013
3Glutamic Acid (Glutamate)FDA Link
01/2016 - 12/2013
3Fluorouracil (Carac)FDA LinkGeneric
10/2015 - 04/2006
3Docetaxel (Taxotere)FDA Link
08/2013 - 11/2011
3leptomycin BIBA
07/2011 - 02/2008
3ProstaglandinsIBA
02/2004 - 03/2002
2pembrolizumabIBA
10/2022 - 01/2020
2durvalumabIBA
01/2022 - 01/2021
2Transcription Factors (Transcription Factor)IBA
01/2022 - 10/2020
2atezolizumabIBA
09/2021 - 01/2020

Therapy/Procedure

79Therapeutics
10/2022 - 05/2003
65Neoadjuvant Therapy
10/2022 - 01/2009
50Drug Therapy (Chemotherapy)
10/2022 - 01/2005
12Immunotherapy
04/2022 - 01/2013
7Adjuvant Chemotherapy
01/2021 - 12/2009
5Aftercare (After-Treatment)
11/2018 - 02/2005
2Hyperthermic Intraperitoneal Chemotherapy
11/2022 - 11/2021
2Combination Drug Therapy (Combination Chemotherapy)
01/2021 - 01/2018
2Radiotherapy
01/2021 - 11/2019